Cipla ties up with Serum Institute to supply vaccines in South Africa

The tie up will enable the drug maker's subsidiary Cipla Medpro to grow its revenue and facilitate regular supply to the South African government

Drug maker Cipla has tied up with Serum Institute of India to distribute vaccines in South Africa.

Cipla operates in South Africa through a subsidiary and the market contributes to about 14% of its consolidated revenue. The tie up will enable its subsidiary Cipla Medpro to grow its revenue and facilitate regular supply to the South African government.

Paul Miller, CEO of Cipla Medpro, South Africa said, "This agreement will enable us to become a significant player in the market. With presence in 140 countries and 1.3 billion doses manufactured and sold, Serum Institute of India is an ideal ally for Cipla Medpro and this partnership will be instrumental in addressing the national vaccine shortage."

 

The two companies already have a tie up for distribution of paediatric vaccines in Europe.